Physician profile
Lori Wilkerson
NPI 1194121723
$3,790.13
in general payments reported to CMS, 2019-2025
27 companies · $671 in 2025
The $671 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $619 · 2023: $852 · 2024: $719 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $946.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $768.22 | 2021-2025 | Freestyle Libre 3, Eterna, Proclaim |
| Amgen INC. | $293.51 | 2021-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $252.41 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $201.46 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Xeris Pharmaceuticals, INC. | $152.56 | 2021-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $144.93 | 2021-2025 | Camzyos, Eliquis |
| Abbvie INC. | $127.42 | 2022-2025 | |
| Lilly USA, LLC | $121.71 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $101.55 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $79.96 | 2021-2024 | Xarelto |
| Pfizer INC. | $74.50 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $63.97 | 2021-2023 | |
| Exact Sciences Corporation | $57.80 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $49.49 | 2021-2024 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.18 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.53 | 2021-2022 | |
| Daiichi Sankyo INC. | $41.91 | 2021-2023 | Injectafer |
| Astellas Pharma US INC | $38.43 | 2023-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $37.45 | 2022-2023 | |
| Vbi Vaccine (Delaware) INC. | $31.20 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.85 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $20.72 | 2022 | |
| Philips North America LLC | $18.76 | 2024 | (Ck7) Extended Holter |
| Nevro Corp. | $16.87 | 2023 | Senza |
| Medtronic, INC. | $14.68 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.62 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Wilkerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.